Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atea Pharmaceuticals, Inc.

3.47
+0.09002.66%
Post-market: 3.470.00000.00%18:08 EDT
Volume:354.23K
Turnover:1.22M
Market Cap:296.96M
PE:-2.10
High:3.51
Open:3.37
Low:3.35
Close:3.38
Loading ...

Atea Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Director Howard Berman

Reuters
·
Yesterday

Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial

TIPRANKS
·
24 Jun

BRIEF-Atea Pharmaceuticals Announces Continued Advancement Of Global Phase 3 Hcv Program

Reuters
·
24 Jun

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 Hcv Program With Dosing of First Patient in C-Forward Outside North America

THOMSON REUTERS
·
24 Jun

Atea Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
21 Jun

Atea Pharmaceuticals (AVIR) Receives a Hold from Morgan Stanley

TIPRANKS
·
16 May

Atea Pharmaceuticals (AVIR) Gets a Buy from William Blair

TIPRANKS
·
13 May

Atea Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Atea Pharmaceuticals Q1 EPS $(0.40) Beats $(0.41) Estimate

Benzinga
·
13 May

BRIEF-Atea Pharmaceuticals Q1 Basic EPS USD -0.4

Reuters
·
13 May

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
13 May

Atea Pharmaceuticals Q1 Pretax Profit USD -34.069 Million

THOMSON REUTERS
·
13 May

Press Release: Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Dow Jones
·
13 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 May

Atea Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
10 May

BRIEF-Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025

Reuters
·
07 May

Atea Pharmaceuticals Announces Full Results From Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (Hcv) Presented at Easl Congress 2025

THOMSON REUTERS
·
07 May

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

GlobeNewswire
·
01 May

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

GlobeNewswire
·
23 Apr

Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program

MT Newswires Live
·
17 Apr